ArticlePloS one2025
Hydroethanolic extract of Schinus terebinthifolia as a promising source of anti-influenza agents: Phytochemical profiling, cheminformatics, molecular docking and dynamics simulations.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although Schinus terebinthifolia (commonly known as Brazilian peppertree) has been documented to possess various biological activities, such as anticancer, antibacterial, and antioxidant properties, its anti-influenza activity has not yet been documented. Here, an aqueous-ethanolic extract (30% v/v ethanol solution), prepared from its aerial parts (leaves and stalks), was established to determine whether it is a rich source of antiviral agents. The hydroethanolic plant extract, with a TPC value of 264.11 mg (GAE)/g DE, exhibits a promising IC50 value of 16.33 μg/mL, similar to that of authentic quercetin (IC50 = 12.72 μg/mL), and approximately 5.34 times higher than that of gallic acid (IC50 = 3.06 μg/mL) as determined by the DPPH assay. This extract contains 1.71 mg of gallic acid (representative marker) per gram of dried plant material, according to HPLC analysis. Using untargeted metabolomics analysis coupled with a series of cheminformatics tools (MetFrag, SIRIUS, CSI:FingerID, and CANOPUS), we ultimately proved that the S. terebinthifolia hydroethanolic extract contains simple phenolics (e.g., methyl gallate, ethyl gallate, and chlorogenic acid), flavonoids (afzelin and myricitrin), dicarboxylic acids, and germacrone. As anticipated, the plant extract exhibited anti-influenza activity with an IC50 of 2.21 μg/mL (CC50 > 50 μg/mL) and did not exert hemolytic activity at the concentration of 2000 μg/mL, underscoring its efficacy as a safe antiviral solution. In silico molecular docking and dynamic simulations suggest that neuraminidase and the cap-binding domain of influenza RNA polymerase (PB2) are preferentially targeted for inhibition by the detected metabolites. Owing to the diverse therapeutic effects of secondary metabolites, the anti-H5N1 activity of the newly developed plant extract is currently under investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.